Uso de factor VII en el control de sangrados perioperatorios: Evidencias actuales

• Rodrigo López B ^[1] ; Nicolás Aeschlimann D ^[1] ; Claudia Carvajal F ^[1] ; Guillermo Lema F ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 137, Nº. 6, 2009, págs. 837-843
• Idioma: español
• Títulos paralelos:
  • Recombinant activated factor VII for perioperative bleeding
• Enlaces
  • Texto completo
• Resumen

  • Recombinant activated factor VII (rFVIIa) is a new haemostatic drug, originally used for the treatment of patients with hemophilia A and B. At the present time it is used for other bleeding conditions such as the perioperative period. When used prophylactically there is a reduction in the number of bleeding episodes but no changes in the need for blood transfusion or other blood products. The adverse effects are arterial or venous thromboembolic events that are mostly related to the severity of the underlying disease of the patient and the concurrent administration of other haemostatic agents, rather than the use of rFVIIa. Its use is recommended when there is a persistent bleeding after the reposition of blood products and when surgical causes of bleeding have been discarded. The cost of the medication should also be considered before its use.